Table 3.

Factors predicting development of second cancers after frontline FCR chemotherapy.

Parameters	Second cancer	Univariate analysis		Multivariate analysis*
	Yes/all in category 66/234 (28%)	OR	P value	OR	P value
Age ≥60 yrs	44/125 (35%)	1.92	0.03	1.53	0.2
<60 yrs	24/109 (22%)
Gender
Male	55/171 (32%)	1.82	0.09
Female	13/63 (21%)
Smoking History
No	38/153 (25%)
Yes	30/81(37%)	1.78	0.05	1.77	0.08
RAI stage
0 1,2	45/163 (27%)
3,4	23/71 (32%)	1.26	0.46
Bulky disease
LN < 5cm	28/112 (25%)
LN≥5cm/ Splenomegaly	40/122 (33%)	1.46	0.19
ALC
<100,000	41/150 (27%)
≥100,000	27/92 (29%)	1.0	0.99
LDH
< 2×ULN	52/200 (26%)
≥ 2×ULN	15/30 (50%)	2.85	0.01	2.78	0.03
β2 macroglobulin (mg/dL)
<3.5	21/97 (22%)
≥3.5	47/133 (35%)	1.98	0.03	1.42	0.32
CD38
Negative	39/143 (27%)
Positive	29/101 (29%)	1.25	0.45
ZAP70
Negative	18/68 (26%)
Positive	35/112 (31%)	1.26	0.5
IGHV Status
Mutated	14/65 (22%)
Unmutated	37/116 (32%)	1.69	0.14
Cytogenetics
Diploid	34/139 (24%)
Abnormal	32/80 (40%)	2.04	0.02	0.84	0.6
FISH
13q	15/64 (23%)
Negative	10/42 (24%)
T12	11/34 (32%)
11q/ATM	11/49 (22%)
17p/p53	13/26 (50%)		0.08
Protocol type
FCR/FCR3/FCR+GM	52/207 (25%)
CFAR/FCMR	16/27 (59%)	3.56	<0.01	2.78	0.01
Number of Cycles
1-3	14/38 (37%)
4-6	14/38 (37%)	0.66	0.66

Abbreviations: yrs,years;LN, lymph node; ALC, absolute lymphocyte count; 2×ULN,twice the upper limit of normal; IGHV, Immunoglobulin variable heavy chain; CFAR: Cyclophosphamide, Fludarabine, Alemtuzumab, Rituximab; FCMR: Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab; FISH, Fluorescence in situ hybridization; ZAP-70, Zeta-chain associated protein kinase 70